Xyall

4 known investors

Xyall builds an automated tissue dissection platform, the Tissector, that combines precision robotics, digital pathology, and workflow software to select and prepare tissue samples for molecular pathology testing. It serves pathology labs in the precision oncology and molecular diagnostics field, bridging histopathology and molecular pathology.

Healthtech Medical Devices Robotics

Investors · 4

BOMTilburg · $540K – $5.4M

Also in the syndicate · 3

Capricorn PartnersleadHealth Investment PartnersSioux Technologies

In the news

Finland's CurifyLabs raises €12 million to expand 3D printing-based medicine compounding | EU-Startupseu-startups.com · Jul 2026

Exclusive: UK HealthTech startup Nul raises €840k in Seed funding to help nullify alcohol dependence | EU-Startupseu-startups.com · Feb 2026

Xyall raises €7.6M to scale automated Tissue Dissection Worldwide - FoundersTodayfounderstoday.news · Feb 2026

Eindhoven’s MedTech startup Xyall secures €7.6 million for global rollout of its automated tissue dissection system | EU-Startupseu-startups.com · Feb 2026

Dutch-Based Xyall Secures €6M To Help Pathologists Obtain More Reliable Molecular Diagnostic Test Results - Marketing In Asiamarketinginasia.com · May 2022

Frequently asked questions

What does Xyall do?: Xyall builds an automated tissue dissection platform, the Tissector, that combines precision robotics, digital pathology, and workflow software to select and prepare tissue samples for molecular pathology testing. It serves pathology labs in the precision oncology and molecular diagnostics field, bridging histopathology and molecular pathology.
Who are Xyall's investors?: Xyall's investors include BOM.